George Eric Davis - 09 Aug 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Legal Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
09 Aug 2022
Net transactions value
-$1,691,926
Form type
4
Filing time
11 Aug 2022, 21:01:09 UTC
Previous filing
11 Jul 2022
Next filing
28 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Sale $355,495 -3,690 -6.3% $96.34 55,251 09 Aug 2022 Direct F1
transaction BMRN Common Stock Options Exercise $3,222,738 +47,526 +86% $67.81 102,777 09 Aug 2022 Direct
transaction BMRN Common Stock Sale $4,559,169 -47,526 -46% $95.93 55,251 09 Aug 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -47,526 -100% $0.000000* 0 09 Aug 2022 Common Stock 47,526 $67.81 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is the weighted average price. The price actually received ranged from $96.310 to $96.425. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F2 The price in column 4 is the weighted average price. The price actually received ranged from $95.540 to $96.400. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.